|
|
Article: Pfizer's Smoking Cessation Medicine Chantix(TM) (Varenicline) Receives FDA Approval.
- Article from:
- PR Newswire
- Article date:
- May 11, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* First new prescription treatment approved for smoking cessation in nearly a decade, received priority review designation by FDA * Addiction to nicotine is a chronic medical condition that makes quitting
smoking difficult; Chantix is a breakthrough treatment specifically developed to block nicotine's effect in the brain * Chantix (1 mg twice daily) nearly doubles the likelihood of quitting versus Zyban(R) (150 mg twice daily) and nearly quadruples the likelihood over placebo
NEW YORK, May 11 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) has approved Pfizer's anti-smoking pill, Chantix(TM) (varenicline). ...